The University of Warwick has authored a new research targeting cancer cells with a new route of attack: a reusable treatment which is activated using a substance found in scores of organisms such as ants and stinging nettles. Department of Chemistry Professor Peter J. Sadler from Warwick has led the research which focuses on an organic-osmium compound named JPC11 targeting a metabolic process relied upon by cancer cells to multiply and survive. JPC11 executes this while converting a vital substance engaged by cancer cells to provide energy for rapid division into an unnatural lactate causing cell destruction.
Chemo-catalyst Treatment Repeatedly Attacks Cancer Cells
The unique reusable and recyclable functionalities of the chemo-catalyst treatment could help to reduce the side effects of chemotherapy with upcoming anticancer drugs given in potentially less toxic, more effective, and smaller doses. However, the research has been more focused on using the compound to treat prostrate and ovarian cancers. In ovarian cancers, the new research has been expected to broaden the scope of anticancer activity and overcome the acquired resistance to existing chemotherapy drugs such as cisplatin and platinum drug.
Significantly, the development has given way for a likelihood of a more selective cancer treatment. This is because JPC11 has been witnessed to target the biochemistry of cancer cells specifically while leaving healthy cells mostly untouched. In comparison, current platinum-based drugs attack non-cancerous cells. JPC11 with sodium formate could manipulate the growth of cancer cells while selectively producing a molecule carrying a specific type of handedness.